Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer (PFE) says regulators have approved $15.2b Hospira (HSP) purchase

Canadian Press August 24, 2015

Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015

Business Wire August 24, 2015

Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition

Business Wire August 24, 2015

Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA® (Meningococcal Group B Vaccine)

Business Wire August 21, 2015

Pfizer Announces European Medicines Agency Validates Marketing Authorization Application for IBRANCE® (palbociclib) in Combination with Endocrine Therapy for the Treatment of HR+/HER2- Metastatic Breast Cancer

Business Wire August 20, 2015

Pfizer Granted Approval From The Canadian Competition Bureau For Hospira Acquisition

Business Wire August 14, 2015

Pfizer Receives Approval from the Australian Competition and Consumer Commission for Pending Acquisition of Hospira

Business Wire August 13, 2015

Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

PR Newswire August 10, 2015

Pfizer Receives Approval From European Commission For Pending Acquisition Of Hospira

Business Wire August 4, 2015

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

Business Wire August 3, 2015

Hospira Reports Second-Quarter 2015 Results

PR Newswire July 29, 2015

Big Pharma Update: Merck (MRK) profit slashed in Q2 as Pfizer (PFE) sales soar

Canadian Press July 28, 2015

PFIZER REPORTS SECOND-QUARTER 2015 RESULTS

Business Wire July 28, 2015

Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology Subsidiary for Kendall Square Research Facility

Business Wire July 22, 2015

America's Most-Preferred Bone Health Brand Launches New Caltrate® Bone & Joint Health Supplement

Business Wire July 21, 2015

Pfizer's Centers For Therapeutic Innovation And Jeffrey Modell Foundation Announce Collaboration to Help Advance Immunological Research

Business Wire July 8, 2015

Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery

Business Wire July 7, 2015

Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets

Business Wire July 2, 2015

Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D

PR Newswire July 2, 2015

Joseph J. Echevarria Elected To Pfizer's Board Of Directors

Business Wire June 25, 2015